Telix Pharmaceuticals Limited (ASX:TLX): What the Proposed ITM Merger Means for Its Cancer Portfolio

Aditi Sarkar

12 November 2026 06:01 PM AEDT

Telix Pharmaceuticals Limited (ASX:TLX): What the Proposed ITM Merger Means for Its Cancer Portfolio

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Telix reported unaudited September-quarter Revenue of USD 245 million, 19% higher year-on-year.
The proposed ITM transaction includes USD 1.65 billion in upfront consideration.
FDA approval of Pixclara expanded the company’s US commercial imaging portfolio.
Shareholder approval and regulatory conditions remain outstanding for the proposed merger.

Telix Pharmaceuticals Limited (ASX:TLX) develops and commercialises radiopharmaceutical products for cancer imaging while advancing therapeutic candidates through clinical development. Its marketed US prostate imaging portfolio includes Illuccix and Gozellix, supported by its radiopharmacy and Manufacturing network. In 2026, Telix combined further commercial activity with a proposed Merger involving Germany-based ITM Isotope Technologies Munich, creating a distinct set of operational, financing and regulatory decisions.

Proposed ITM Merger and Conditions

On 21 September 2026, Telix Pharmaceuticals Limited (ASX:TLX) announced an agreement for a proposed combination with ITM. The upfront enterprise consideration is USD 1.65 billion on a cash-free, debt-free basis. The announced terms contemplate approximately USD 1.25 billion in Telix shares for ITM shareholders, alongside assumed net Debt and transaction adjustments. Further contingent consideration of up to USD 700 million depends on specified regulatory and commercial milestones for ITM-11.

ITM develops radiopharmaceutical therapies and supplies medical isotopes, including lutetium-177. Its investigational ITM-11 therapy targets gastroenteropancreatic neuroendocrine tumours. The proposal is intended to connect Telix’s commercial imaging operation with therapeutic development and isotope supply; it does not establish that ITM-11 has regulatory approval or that the combination has closed. A general meeting is scheduled for 1 December 2026, and other closing conditions also apply.

Commercial Revenue and Updated Guidance

For the September 2026 quarter, Telix Pharmaceuticals Limited (ASX:TLX) reported unaudited group revenue of USD 245 million, versus USD 206 million in the comparable 2025 quarter and USD 247 million in June 2026. Precision Medicine contributed USD 201 million, compared with USD 155 million a year earlier. Telix Manufacturing Solutions generated USD 44 million, versus USD 47 million in the previous corresponding quarter.

Management reaffirmed expectations for FY26 revenue and other income exceeding USD 1 billion, with revenue trending towards the upper end of the USD 950 million to USD 970 million guidance range and approximately USD 40 million in other income. Research and Development expenditure guidance was narrowed to USD 240 million to USD 260 million. These amounts are management forecasts, not final audited results.

Imaging Approvals and Clinical Programmes

An important 2026 milestone for Telix Pharmaceuticals Limited (ASX:TLX) was US Food and Drug Administration approval of Pixclara for glioma imaging. Initial commercial doses were administered in September. The BiPASS prostate imaging study completed enrolment and received Fast Track designation, but those developments do not amount to Marketing approval for that indication.

Other programmes remain at different regulatory stages. The company is preparing a resubmission for the kidney cancer imaging product Zircaix after a Complete Response Letter concerning manufacturing observations. Its investigational therapeutic programmes include the ProstACT Global Phase 3 study and the OPTIMAL-PSMA Phase 2 study, with data from the latter expected in H1 2027. Trial results and approval decisions remain uncertain.

Execution Priorities and Outstanding Risks

The proposed ITM combination introduces potential integration requirements, additional financing exposure and the possibility of contingent milestone payments. Telix Pharmaceuticals Limited (ASX:TLX) must also navigate competition in prostate cancer imaging, commercial manufacturing requirements and clinical development costs. A proposed share issuance would change the ownership interests of existing holders if the merger closes.

The next clearly identified decisions concern the December Shareholder meeting, remaining transaction clearances, the Zircaix resubmission and trial progress. Telix’s already approved imaging products generate revenue today; the Acquisition proposal and investigational therapies represent separate future possibilities rather than completed commercial outcomes.

Key Insights

Telix Pharmaceuticals Limited (ASX:TLX) generated higher year-on-year quarterly revenue and secured another US imaging approval while proposing a material expansion through ITM. Completion of that transaction remains conditional, and its investigational programmes carry clinical and regulatory uncertainties. Commercial imaging performance and transaction execution will be distinct measures of progress.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.